Phase 3 Study Comparing IN10018 Plus D-1553 to Standard Therapy for First-Line Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer with KRAS G12C Mutation
Led by InxMed (Shanghai) Co., Ltd. · Updated on 2026-03-03
400
Participants Needed
11
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the combination of IN10018 and D-1553 compared to the standard anti-PD-1 monoclonal antibody therapy with platinum and pemetrexed for treating adults with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC that has a KRAS G12C mutation. This phase III, randomized, open-label study is based on earlier data showing that IN10018 combined with D-1553 may enhance antitumor activity and delay resistance through multiple biological mechanisms.
Participants are randomly assigned to one of two treatment groups. One group receives IN10018 100 mg orally once daily and D-1553 600 mg orally twice daily in 21-day cycles until disease progression or unacceptable side effects. The other group receives Tislelizumab 200 mg intravenously every 3 weeks combined with either Carboplatin or Cisplatin intravenously every 3 weeks for up to 4 cycles plus Pemetrexed intravenously every 3 weeks until disease progression.
During the study, participants will have regular assessments to monitor tumor response, side effects, and survival. Key outcome measures include progression-free survival over 36 months, response rates, overall survival up to 60 months, and safety evaluations. The study aims to track disease control and duration of response while monitoring adverse events throughout the treatment period.
CONDITIONS
Brief Title
A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
Research Team
S
Shu Fang Project Manager, bachelor
J
Jack Zhang Clinical Trial Manager, bachelor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
KRAS G12C mutation confirmed by central laboratory
No prior systemic therapy for advanced or metastatic NSCLC
At least one measurable lesion per RECIST v1.1
ECOG performance status of 0 or 1
Adequate organ function
Life expectancy of at least 3 months as judged by Investigator
Male and female subjects of reproductive potential must agree to use effective contraception during and for 6 months after treatment
You will not qualify if you...
Other histological subtypes of NSCLC (e.g., small cell or neuroendocrine)
Active or untreated CNS metastases or carcinomatous meningitis
Prior treatment with KRAS G12C inhibitors, FAK inhibitors, or immune checkpoint inhibitors
Presence of another known driver mutation with approved targeted therapy (e.g., EGFR, ALK, ROS1)
Uncontrolled cardiovascular disease, active severe infection, interstitial lung disease, or autoimmune disease needing systemic therapy
History of another malignancy within 5 years except curatively treated low-risk cases
Gastrointestinal conditions that may interfere with oral drug absorption
Known active hepatitis B, hepatitis C, or HIV infection
Receipt of live vaccine within 30 days before first dose
Pregnant or breastfeeding women
Psychiatric or substance abuse disorders interfering with study compliance
Participation in another interventional clinical study
Any condition judged by Investigator to interfere with participation or study results
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Up to 36 months
Participants receive either IN10018 combined with D-1553 orally in 21-day cycles or Tislelizumab with platinum and Pemetrexed intravenously every 3 weeks. Treatment continues until disease progression or unacceptable toxicity.
Repeated visits every 3 weeks during treatment cycles
Follow-up
Duration - Up to 24 months after treatment
Participants are monitored for long-term outcomes including survival and safety after treatment ends.
Periodic visits for outcome assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Using 3-D Virtual Lung Resection to Predict Lung Function After VATS Surgery for Non-Small Cell Lung Cancer
Early Evaluation of Neoadjuvant Immunotherapy Response
Using 68Ga-grazytracer PETCT in Resectable Non-Small Cell Lung Cancer
Patients Aged 18 to 75 Years
Evaluating Calderasib with Subcutaneous Pembrolizumab Versus Pembrolizumab Plus Chemotherapy
for KRAS G12C-Mutant Advanced Non-Small Cell Lung Cancer
Randomized Study of Adjuvant Cemiplimab Versus Observation in Patients With Surgically Removed Stage II-IIIA Non-Small Cell Lung Cancer Without Prior Chemotherapy
Evaluating Adjuvant Intismeran With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa Compared to Placebo in High-Risk Stage I Non-Small Cell Lung Cancer
Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in People With Locally Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer After Chemoradiotherapy
Phase 2 Study of TQB2102 Injection for Treating Locally Advanced or Metastatic Non-Small Cell Lung Cancer with HER2 Gene Abnormality
Phase I Study of Intravenous CEA-Targeted CAR-T Therapy for Advanced CEA Positive Solid Tumors
Testing Safety and Effectiveness of BNT326 and Pumitamig Combination Therapy in Advanced Non-small Cell Lung Cancer
Phase IIIb Study to Evaluate the Safety and Effectiveness of Vebreltinib PLB1001 in Adults With Advanced or Metastatic Non-Small Cell Lung Cancer Having MET Exon 14 Mutation
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial.